Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus

Simply Wall St.

Mar 20

Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620578889"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620578889\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620578889?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-20 13:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620578889","market":"hk","top_or_hot":-1,"title":"Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus","media":"Simply Wall St.","content":"<div>\n<p>Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 13:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli","article_id":"2620578889","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620578889","pubTimestamp":1773983450,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy and pipeline plans.\nSee our latest analysis for Mesoblast.\nThose R&D Day plans come after a tough stretch for the share price, with a 30 day share price return of a 14.11% decline and a year to date share price return of a 25.27% decline, even though the three year total shareholder return is up...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK4006":"钢铁","MSB":"美莎比信托","MSB.AU":"MESOBLAST LTD","BK7067":"生物科技","BK7501":"新冠治疗股"},"translate_title":"Mesoblast(ASX：MSB)第一个研发日的估值检查将管道和增长计划置于焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1.5,"MSB":1.5},"content_text":"Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy and pipeline plans. See our latest analysis for Mesoblast. Those R&D Day plans come after a tough stretch for the share price, with a 30 day share price return of a 14.11% decline and a year to date share price return of a 25.27% decline, even though the three year total shareholder return is up 133.50%. This hints that sentiment has cooled recently despite a stronger multi year record. If Mesoblast's R&D pipeline has your attention, it can be useful to see what else is shaping healthcare and biotech. Check out 9 healthcare AI stocks So with Mesoblast shares down over the past year but still showing a stronger three year total return, and trading below some valuation estimates, are you looking at an overlooked opportunity or a market that is already pricing in future growth? AdvertisementMost Popular Narrative: 46% Undervalued Mesoblast's most followed narrative pegs fair value at A$3.83 per share, compared with the latest close of A$2.07, framing the current price as a sizable discount.  The heart failure program for rexlemestrocel L, with RMAT designation and FDA feedback that existing trial data could support an accelerated approval filing alongside a planned confirmatory study, gives Mesoblast a potential entry into a very large cardiovascular market. Outcomes would primarily influence long term revenue scale and the path to sustainable earnings.  Read the complete narrative. Want to see what is sitting behind that gap between price and fair value? The narrative focuses on expectations for revenue growth, margin expansion and a richer future earnings multiple. Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could change quickly if Ryoncil uptake stays weak relative to high cash burn, or if key trials face delays or disappointing readouts. Find out about the key risks to this Mesoblast narrative. Another View: Multiples Send A Very Different Signal While the popular narrative and analyst targets frame Mesoblast as undervalued, its current P/S of 28.8x is more than double the Australian Biotechs average of 13.7x and far above an estimated fair ratio of 4.6x. That kind of gap can point to valuation risk rather than a clear discount, so which signal do you trust? See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at Mar 2026Next Steps With mixed signals across valuation methods, this is the moment to look through the numbers yourself and decide where you stand. A good place to start is by weighing up the company's 3 key rewards Looking for more investment ideas? If Mesoblast has sparked your interest, do not stop here. Broaden your watchlist with fresh ideas that match different goals, risk levels and income needs.  Target potential mispricings by scanning 5 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying metrics. Strengthen your income stream by reviewing 8 dividend fortresses that focus on higher yielding payouts backed by solid profiles. Dial down risk by filtering for 7 resilient stocks with low risk scores that screen for businesses with more resilient characteristics and lower overall risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}